ANXA1 and proximal spinal muscular atrophy: ANXA1 (Annexin A1) has anti-inflammatory activity and, given that neuroinflammation takes part in SMA pathogenesis [34], the up-regulation of ANXA1 may be a protective consequence of nusinersen treatment.